A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/03/2004	EP1472256A1 Piperidine derivatives
11/03/2004	EP1472255A1 Aza-arylpiperazines
11/03/2004	EP1472253A1 Sulphonyl compounds with 5 -ht6 receptor affinity
11/03/2004	EP1472252A1 Substituted fused pyrazolecarboxylic acid arylamides and related compounds
11/03/2004	EP1472251A1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
11/03/2004	EP1472250A1 Anticholinergic agents, method for producing the same and use thereof as medicaments
11/03/2004	EP1472249A1 Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments
11/03/2004	EP1472248A1 Modulators of acetylcholine receptors
11/03/2004	EP1472247A1 Antimicrobial thiadiazinone derivatives useful in treatment of bacterial infections
11/03/2004	EP1472245A2 Heteroaryl compounds useful as inhibitors of gsk-3
11/03/2004	EP1472244A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
11/03/2004	EP1472243A1 Piperidine derivatives and their use as antagonists of tachykinins
11/03/2004	EP1472242A1 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
11/03/2004	EP1472241A1 Cytoprotective benzofuran derivatives
11/03/2004	EP1472240A1 Drechslera anole derivatives, method for the production and use thereof
11/03/2004	EP1472237A1 Catechol bioisosteres
11/03/2004	EP1472236A1 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide
11/03/2004	EP1472234A1 Quinazolinone derivatives and their use as cb agonists
11/03/2004	EP1472233A1 Pyrimidine compounds
11/03/2004	EP1472231A1 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
11/03/2004	EP1472230A2 Ansamycins having improved pharmacological and biological properties
11/03/2004	EP1472229A1 5-ring heterocycles used as antiviral agents
11/03/2004	EP1472228A1 Process for the manufacture of hmg-coa reductase inhibitors
11/03/2004	EP1472226A1 Heterocyclic amide compounds as apolipoprotein b inhibitors
11/03/2004	EP1472225A2 2-piperazine-pyridines useful for treating pain
11/03/2004	EP1472224A2 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/03/2004	EP1472223A1 Gamma secretase inhibitors
11/03/2004	EP1472222A1 Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
11/03/2004	EP1472221A2 Substituted indoles, method for production and use thereof for the inhibition of pain
11/03/2004	EP1472220A1 Crystalline (r-(r,r))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
11/03/2004	EP1472219A1 Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
11/03/2004	EP1472216A2 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
11/03/2004	EP1472215A2 (oxime)carbamoyl fatty acid amide hydrolase inhibitors
11/03/2004	EP1472214A2 Compounds for inhibiting insulin secretion and methods related thereto
11/03/2004	EP1472209A2 Lipoxin a4 analogs
11/03/2004	EP1472208A1 Novel 3-aryl-2,5-dihydroxy-1,4-benzoquinone derivatives, their preparation method and pharmaceutical compositions containing same
11/03/2004	EP1471974A1 Tumor necrosis factor combined with interferon in demyelinating diseases
11/03/2004	EP1471970A2 NOVEL MAMMALIAN MULTIPOTENT STEM CELLS AND COMPOSITIONS, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION THEREOF
11/03/2004	EP1471944A2 Pharmaceutical composition which improves in vivo gene transfer
11/03/2004	EP1471934A2 Kinases involved in the regulation of energy homeostasis
11/03/2004	EP1471931A2 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
11/03/2004	EP1471927A2 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
11/03/2004	EP1471924A1 Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
11/03/2004	EP1471923A1 Amido macrolides
11/03/2004	EP1471921A2 Counteracting bioprosthetic calcification
11/03/2004	EP1471920A2 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol
11/03/2004	EP1471919A1 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist
11/03/2004	EP1471918A2 Use of modified pyrimidine compounds to promote stem cell migration and proliferation
11/03/2004	EP1471917A1 Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
11/03/2004	EP1471916A2 Treatment of rheumatoid arthritis using imatinie
11/03/2004	EP1471915A2 2,4-pyrimidinediamine compounds and their uses
11/03/2004	EP1471914A1 Pharmaceutical composition for regeneration of cirrhotic liver
11/03/2004	EP1471913A2 Treatment of sleep disorders using sleep target modulators
11/03/2004	EP1471912A1 Method of promoting neuronal growth
11/03/2004	EP1471911A1 Novel crystalline forms of gatifloxacin
11/03/2004	EP1471910A2 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
11/03/2004	EP1471909A1 Pharmaceutical composition and method for treating disorders of the central nervous system
11/03/2004	EP1471908A1 Process for preparing losartan potassium with improved flowability
11/03/2004	EP1471907A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases
11/03/2004	EP1471906A1 Stimulation of cpt-1 as a means to reduce weight
11/03/2004	EP1471905A1 Use of cholinesterase antagonists to treat insulin resistance
11/03/2004	EP1471904A1 Carnitine in the treatment of geriatric depression
11/03/2004	EP1471903A2 Use of glutathione synthesis stimulating compounds in reducing insulin resistance
11/03/2004	EP1471902A1 Methods for treating hearing loss
11/03/2004	EP1471901A1 Spermidine derivatives for the treatment of chronic neurodegenerative diseases
11/03/2004	EP1471900A1 Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor agonist for the treatment of inflammatory and allergic conditions
11/03/2004	EP1471899A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias
11/03/2004	EP1471898A1 Lutein/zeaxanthin for glare protection
11/03/2004	EP1471897A2 Use of phosphodiesterase antagonists to treat insulin resistance
11/03/2004	EP1471896A1 Formulations for inhalation
11/03/2004	EP1471895A1 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
11/03/2004	EP1471894A1 Cyclodextrines for use as suspension stabilizers in pressure-liquefied propellants
11/03/2004	EP1471892A2 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
11/03/2004	EP1471890A2 Pharmaceutical dosage form for mucosal delivery
11/03/2004	EP1471889A2 Oral pediatric trimethobenzamide formulations and methods
11/03/2004	EP1471888A2 Oral trimethobenzamide formulations and methods
11/03/2004	EP1471887A2 Nanoparticulate compositions having lysozyme as a surface stabilizer
11/03/2004	EP1471884A1 Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier
11/03/2004	EP1471881A2 Use of a compound inactivating the kinase a protein in a composition containing a cosmetically acceptable medium in order to lighten the skin
11/03/2004	EP1471879A1 Topical glycopyrrolate product
11/03/2004	EP1471876A1 Method of enhancing hair growth
11/03/2004	EP1471874A1 Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
11/03/2004	EP1471872A2 Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
11/03/2004	EP1471871A2 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
11/03/2004	EP1471870A2 Use of lipid conjugates in the treatment of disease
11/03/2004	EP1471853A2 Medical device with coating that promotes endothelial cell adherence and differentiation
11/03/2004	EP1471818A2 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/03/2004	EP1404315B1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones
11/03/2004	EP1392697B1 Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino 2,3-f]quinoline
11/03/2004	EP1383399B1 Nutritional supplement to treat macular degeneration
11/03/2004	EP1377550B1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
11/03/2004	EP1347974B1 Aminotriazolopyridiine derivatives as adenosine receptor ligands
11/03/2004	EP1339716B1 lactam-substituted pyrazolopyridine derivatives
11/03/2004	EP1337271B1 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
11/03/2004	EP1317425B1 Resorcinol derivatives
11/03/2004	EP1313732B1 Oxindole derivatives
11/03/2004	EP1309582B1 Method for the preparation of citalopram
11/03/2004	EP1309581B1 Method for the preparation of citalopram
11/03/2004	EP1305003B1 Use of a combination of active substances comprising bioquinones for the manufacture of cosmetic or dermatological compositions for the treatment or the prevention of dandruff
11/03/2004	EP1294677B1 Benzophenones and sulfones as inhibitors of glycine uptake

1 ... 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 4922 4923 4924 4925 ... 7860